New drug shows promise for bulging eyes in thyroid disease
NCT ID NCT06384547
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 3 trial tested a drug called VRDN-001 in 231 people with thyroid eye disease (TED). The drug works by blocking a receptor involved in inflammation and swelling. The main goal was to check safety and tolerability, with secondary goals including measuring changes in eye bulging. Participants received five infusions of either a low or high dose of the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VRDN-001 (a monoclonal antibody that blocks the IGF-1 receptor)
- What this could lead to
- If successful, this could lead to a new treatment option that reduces eye bulging and inflammation in people with thyroid eye disease.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. The drug may cause side effects, and it is not a cure—patients may still need ongoing care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ
Wroclaw, 53-114, Poland
-
AP-HP - Hôpital de la Pitié Salpétrière
Paris, 75013, France
-
Advancing Research International, LLC
Los Angeles, California, 90023, United States
-
Advancing Research International, LLC
Las Vegas, Nevada, 89144, United States
-
Baylor College of Medicine (BCM) - Ophthalmology
Houston, Texas, 77030, United States
-
CH Nice
Nice, 06000, France
-
CHU d'Angers
Angers, 49100, France
-
Centre Hospitalier National D'ophtalmologie
Des Quinze Vingts Paris, 75012, France
-
Clinica Bonanova de Cirugia Ocular
Barcelona, 08022, Spain
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
Clínica Universidad de Navarra
Madrid, 28027, Spain
-
Cockerham Eye Consultants, PC
San Diego, California, 92108, United States
-
Complexo Hospitalario Universitario de Santiago-Hospital Médico-Cirúrxico de Conxo
Santiago de Compostela, A Coruña, 15706, Spain
-
Edward Jenner Research Group Center LLC
Plantation, Florida, 33317, United States
-
FOMAT Medical Research
Santa Maria, California, 93454, United States
-
Fraser Eye Care Center
Fraser, Michigan, 48026, United States
-
Guy's and St. Thomas NHS Trust
London, SE1 7EH, United Kingdom
-
Hospital Arruzafa
Córdoba, 14012, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Virgen De La Macarena, Servicio de Oftalmología
Seville, 41071, Spain
-
Johannes Gutenberg-University Medical Center
Mainz, 55131, Germany
-
KU Medical Center, University of Kansas
Kansas City, Kansas, 66103, United States
-
Kahana Oculoplastic & Orbital Surgery
Livonia, Michigan, 48152, United States
-
Massachusetts Eye and Ear
Boston, Massachusetts, 02114, United States
-
Med-Care Research Inc.
Miami, Florida, 33125, United States
-
Miguel Servet University Hospital, Clinical Trials Unit
Zaragoza, 50009, Spain
-
NZOZ E-Vita
Bialystok, 15-879, Poland
-
Neuro-Eye Clinical Trials
Houston, Texas, 77074, United States
-
Neuro-Ophthalmology of Texas, PLLC
Houston, Texas, 77074, United States
-
New York Eye Ear Infirmary of Mount Sinai
New York, New York, 10003, United States
-
North Shore Eye Surgery
Sydney, 2065, Australia
-
Northwick Park Hospital
London, HA1 3UJ, United Kingdom
-
Ophthalmic Consultants of Boston
Weymouth, Massachusetts, 02189, United States
-
Panstwowy Instytut Medyczny MSWiA
Warsaw, 02-507, Poland
-
Rutgers- New Jersey Medical School- Newark
Newark, New Jersey, 07103, United States
-
Santa Familia PTG Lodz
Lódz, 90-302, Poland
-
Sarasota Retina Institute
Sarasota, Florida, 34231, United States
-
Sina Medical Center LLC
Homestead, Florida, 33034, United States
-
Specjalistyczny Osrodek Okulistyczny Oculomedica
Bydgoszcz, 85-870, Poland
-
Stanford Byers Eye Institute
Palo Alto, California, 94303, United States
-
Sydney Eye Hospital
Sydney, 2000, Australia
-
United Medical Research Institute
Inglewood, California, 90301, United States
-
University Health Diabetes, Endocrinology & Nephrology Center
Kansas City, Kansas, 64108, United States
-
University of Colorado - Dept of Ophthalmology
Aurora, Colorado, 80045, United States
-
University of Minnesota, Department of Ophthalmology and Visual Neurosciences
Minneapolis, Minnesota, 55455, United States
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
-
Universitätsmedizin Göttingen
Göttingen, 37075, Germany
-
Vision Medical Research Inc.
Orland Park, Illinois, 60462, United States
-
West Virginia University Eye Institute
Morgantown, West Virginia, 26506, United States
-
Western Eye Hospital, Imperial College NHS Trust
London, NW1 5QH, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an experimental drug reduce eye bulging in thyroid eye disease?
- Can a new drug ease bulging eyes in thyroid disease?
- New drug IBI3031 enters first human trial for thyroid eye disease
- New hope for thyroid eye disease: drug shows promise in Steroid-Resistant patients
- Your phone camera could soon spot eye disorders
- Promising drug trial for thyroid eye disease halted early